000			02193 a2200625 4500
005			20250516001426.0
264		0	_c20101221
008			201012s 0 0 eng d
022			_a1029-2403
024	7		_a10.3109/10428194.2010.499486 _2doi
040			_aNLM _beng _cNLM
100	1		_aLi, Xing
245	0	0	_aPrognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. _h[electronic resource]
260			_bLeukemia & lymphoma _cSep 2010
300			_a1678-85 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAcute Disease
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aBilirubin _xmetabolism
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDNA, Viral _xgenetics
650	0	4	_aDoxorubicin _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHepatitis B _xdrug therapy
650	0	4	_aHepatitis B virus _xphysiology
650	0	4	_aHumans
650	0	4	_aLiver Function Tests
650	0	4	_aLymphoma, B-Cell, Marginal Zone _xvirology
650	0	4	_aLymphoma, Follicular _xvirology
650	0	4	_aLymphoma, Large B-Cell, Diffuse _xvirology
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPolymerase Chain Reaction
650	0	4	_aPrednisone _xadministration & dosage
650	0	4	_aPrognosis
650	0	4	_aProthrombin Time
650	0	4	_aRituximab
650	0	4	_aSurvival Rate
650	0	4	_aVincristine _xadministration & dosage
650	0	4	_aVirus Activation _xdrug effects
700	1		_aLin, Qu
700	1		_aDong, Min
700	1		_aWen, Jing-Yun
700	1		_aWei, Li
700	1		_aMa, Xiao-Kun
700	1		_aChen, Zhan-Hong
700	1		_aWu, Xiang-Yuan
773	0		_tLeukemia & lymphoma _gvol. 51 _gno. 9 _gp. 1678-85
856	4	0	_uhttps://doi.org/10.3109/10428194.2010.499486 _zAvailable from publisher's website
999			_c20140500 _d20140500